Comparison of induction chemotherapy with/without PD-1 inhibitors followed by concurrent chemoradiotherapy in locally advanced head and neck squamous cell carcinoma.

In contrast, the recently reported phase III KEYNOTE-689 trial demonstrated that perioperative pembrolizumab (neoadjuvant plus adjuvant) significantly improved EFS when added to surgery and risk-adapted adjuvant radiotherapy with or without cisplatin, and was associated with a clear trend toward improved overall survival in the PD-L1 CPS ≥10 population[ 16 ].

also in 19,460 other papers